US EditionNovo Nordisk Patent Expiry Opens Door to Cheaper Weight-Loss Drugs in India
Indian drugmakers plan to offer semaglutide generics at 50-60% discounts, expanding access amid concerns about market overcrowding and uneven regulation.
- Novo Nordisk's patent on semaglutide expires this week, allowing Sun Pharma and Dr. Reddy's to launch cheaper generics in India, with some expected as soon as Saturday.
- High local demand and rising obesity underpin India's market growth, with Pharmarack projecting expansion from about 15 billion to 80 billion rupees by 2030 and some patients spending about 30,000 rupees monthly.
- Indian generics plan discounts of at least 50% to 60%, with retail quotes of 2,500 to 3,500 rupees, while many use 'sema' brand names that may overwhelm doctors and pharmacists.
- Doctors and pharmacists' prescription enforcement will determine market winners, as generics challenge Novo Nordisk and Eli Lilly in India, said Sheetal Sapale.
- Market watchers warn that weaker players will exit within two to three years, and misuse risks could lead to regulatory tightening, said Salil Kallianpur, 'With high demand, falling prices and multiple brands, you may see direct pharmacy purchases, distributor-level leakages, or cosmetic or lifestyle use especially in urban markets'.
12 Articles
12 Articles
Novo's patent on semaglutide in the Indian market expires on Friday, opening the door to cheaper alternatives.
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
Weight-loss drugs to be offered in generic form
Semaglutide, the weight-loss and diabetes drug better known as Ozempic and Wegovy, will soon be available in generic form for 40% of the world’s population. The widely popular medication briefly made manufacturer Novo Nordisk Europe’s most valuable firm. Pharma regulations in China, India, Turkey, and elsewhere mean that Novo’s patent, and thus its monopoly, expires Saturday, and manufacturers are racing to produce low-cost versions. It is bad n…
Coverage Details
Bias Distribution
- 50% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
